BioScrip Inc. (NASDAQ:BIOS) shares saw an uptick in trading volume on Monday . 510,793 shares were traded during mid-day trading, an increase of 10% from the previous session’s volume of 462,716 shares.The stock last traded at $2.87 and had previously closed at $2.75.

Separately, Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Friday, June 17th.

The firm has a 50-day moving average price of $2.70 and a 200 day moving average price of $2.55. The company’s market capitalization is $330.25 million.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Monday, August 8th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.05. BioScrip had a negative net margin of 5.63% and a negative return on equity of 609.04%. The company earned $232.50 million during the quarter, compared to analyst estimates of $229.58 million. The business’s quarterly revenue was down 11.4% compared to the same quarter last year. On average, equities research analysts predict that BioScrip Inc. will post ($0.27) earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. increased its position in BioScrip by 1.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 209,910 shares of the company’s stock valued at $536,000 after buying an additional 3,360 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new position in BioScrip during the second quarter valued at about $152,000. First Light Asset Management LLC increased its position in BioScrip by 592.5% in the second quarter. First Light Asset Management LLC now owns 2,092,082 shares of the company’s stock valued at $5,335,000 after buying an additional 1,789,972 shares during the last quarter. Highbridge Capital Management LLC acquired a new position in BioScrip during the second quarter valued at about $867,000. Finally, Iguana Healthcare Management LLC acquired a new position in BioScrip during the second quarter valued at about $1,913,000. Hedge funds and other institutional investors own 85.91% of the company’s stock.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

5 Day Chart for NASDAQ:BIOS

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.